45 results on '"Rönnelid, Johan"'
Search Results
2. Additional file 3 of Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity
3. Additional file 1 of Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity
4. Additional file 3 of Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity
5. The CN-index of hnRNP-DL Predicts an Individual 'Window of Treatment Success' in RA Patients
6. sj-pdf-1-lup-10.1177_09612033211014570 - Supplemental material for Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE
7. sj-pdf-2-lup-10.1177_09612033211014570 - Supplemental material for Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE
8. A Comprehensive Evaluation of the Relationship Between Different IgG and IgA Anti-Modified Protein Autoantibodies in Rheumatoid Arthritis
9. sj-pdf-1-lup-10.1177_0961203320945387 - Supplemental material for High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients
10. Additional file 3 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
11. Additional file 7 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
12. Additional file 6 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
13. Additional file 6 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
14. Additional file 7 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
15. Additional file 4 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
16. Additional file 1 of The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis
17. Additional file 4 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
18. Additional file 8 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
19. Additional file 8 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
20. Additional file 2: Figure S1. of Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis
21. Additional file 1: Table S1. of Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis
22. Additional file 2: Figure S1. of Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis
23. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis
24. Additional file 5: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
25. Additional file 1 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
26. Additional file 1: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
27. Additional file 2: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
28. Additional file 5 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
29. Additional file 4: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
30. Additional file 9 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
31. Additional file 1 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
32. Additional file 5 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
33. Additional file 2 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
34. Additional file 5: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
35. Additional file 9 of Presence of autoantibodies in 'seronegative' rheumatoid arthritis associates with classical risk factors and high disease activity
36. Additional file 1 of The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual 'window of treatment success' in RA patients
37. Additional file 3: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
38. Additional file 1 of The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual 'window of treatment success' in RA patients
39. Additional file 3: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
40. Additional file 2: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
41. Additional file 6: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
42. Additional file 1: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
43. Additional file 6: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
44. Additional file 4: of Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
45. Increased IL-17A secretion in response to Candida albicans in autoimmune polyendocrine syndrome type 1 and its animal model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.